Physician profile
John Willis
NPI 1093730160
$9,663.88
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,275 · 2020: $1,789 · 2021: $3,108 · 2022: $2,125 · 2023: $324 · 2024: $41.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $365.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,934.22 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,749.13 | 2019-2023 | |
| Amgen INC. | $1,295.80 | 2019-2022 | |
| Horizon Therapeutics Plc | $621.80 | 2019-2022 | |
| Glaxosmithkline, LLC. | $359.65 | 2019-2022 | |
| Pfizer INC. | $316.13 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $258.08 | 2021-2022 | |
| Ucb, INC. | $252.46 | 2019-2024 | Cimzia |
| Mallinckrodt Hospital Products INC. | $208.21 | 2020-2023 | Acthar |
| Lilly USA, LLC | $194.55 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $190.95 | 2019-2022 | |
| Genentech USA, INC. | $178.16 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $169.94 | 2019-2022 | |
| Janssen Biotech, INC. | $164.02 | 2019-2022 | |
| Celgene Corporation | $146.74 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $128.89 | 2019 | |
| Bioventus LLC | $71.97 | 2021-2022 | |
| Genzyme Corporation | $60.80 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $52.36 | 2020-2021 | |
| Organon LLC | $33.61 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $31.07 | 2021 | |
| Ani Pharmaceuticals, INC. | $27.51 | 2022 | |
| Merck Sharp & Dohme LLC | $23.75 | 2019-2021 | |
| Radius Health, INC. | $23.45 | 2019 | |
| Hikma Pharmaceuticals USA | $23.43 | 2022 | |
| Sobi, INC | $22.76 | 2022 | |
| Gilead Sciences, INC. | $20.44 | 2019 | |
| Depuy Synthes Sales INC. | $19.27 | 2021 | |
| Antares Pharma, INC. | $18.73 | 2019 | |
| Pacira Therapeutics, INC. | $18.16 | 2020 | |
| Boston Scientific Corporation | $17.16 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.50 | 2021 | |
| Avanos Medical | $14.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.